GE Healthcare and G-CON have combined capabilities to offer drug developers ‘readily deployable’ manufacturing platforms for cell therapies and viral vectors.
Fujifilm has launched an upgrade to its subsidiaries manufacturing capabilities, by increasing capacity by 50% at an existing facility and building an entirely new site for cell technology.
The UK has a ‘rich and vibrant’ advanced therapeutic manufacturing sector well placed to attract companies post-Brexit, says Keith Thompson, CEO of CGTC.
BIA’s Bioscience Forum brought together four experts on cell and gene manufacture to discuss what difficulties are being faced in the industry and how they are reacting to them.
